Separate and Combined Extrapancreatic Effects of the Incretin Hormones

NCT05177653 · Completed

Last updated 2026-05-28

This clinical trial tests how two gut hormones, separately and together, affect blood sugar levels in people who have had their pancreas removed.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 13 people

Who can join Ages 30–70 · all sexes

Timeline Started 2022-04 · est. completion 2023-03

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT05177653 ↗

Description as written by the study sponsor.

The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) is secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. The hormones also exert effects outside the pancreas, but especially for GIP, these are poorly investigated. Because of this, only GLP-1 based drugs (GLP-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. Nonetheless, a new drug is in clinical development: a combined GIP-GLP-1-receptor agonist (tirzepatide), which has shown better results than GLP-1 alone. The mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of GIP and GLP-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.

Treatments tested

Intravenous infusion Other

GIP receptor antagonist (GIP(3-30)NH2)
Intravenous infusion Other

GLP-1 receptor antagonist (exendin(9-39)NH2)
Intravenous infusion Other

GIP(3-30)NH2 and exendin(9-39)NH2
Intravenous infusion Other

Saline

Main thing measured	Changes in plasma levels of glucose between interventions assessed through frequently blood sampling during the experimental days
Sponsor	University Hospital, Gentofte, Copenhagen
Conditions studied	Pancreatectomy; Hyperglycemia
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05177653 ↗